Gefitinib

Generic Name: Gefitinib

Brand Names: Iressa, Gefitinib Mylan

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₄ClFN_₄O_₃

CAS Number: 184475-35-2

Unique Ingredient Identifier: S65743JHBS

Background: Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa.

Indication: For the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.

Associated Conditions: Metastatic Non-Small Cell Lung Cancer

Associated Therapies: -

Clinical Trials

Gefitinib Combine Radiotherapy as Therapy for Patients With NSCLC Harbouring Sensitive Mutations of EGFR

Not Applicable

Not yet recruiting

Conditions: Lung Cancer

Interventions: Drug: Gefitinib

First Posted Date: 2017-12-22

Last Posted Date: 2017-12-22

Lead Sponsor: Qilu Pharmaceutical Co., Ltd.

Target Recruit Count: 50

Registration Number: NCT03381430

Locations: 🇨🇳
China-Japan Friendship Hospital, Beijing, China

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

Phase 1

Active, not recruiting

Conditions: EGFR-mutant Non-small Cell Lung Cancer

Interventions: Drug: EGF816
Drug: LXH254
Drug: trametinib
Drug: ribociclib
Drug: gefitinib
Drug: INC280

First Posted Date: 2017-11-06

Last Posted Date: 2024-07-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 105

Registration Number: NCT03333343

Locations: 🇨🇳
Novartis Investigative Site, Taipei, Taiwan

A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer

Phase 2

Active, not recruiting

Conditions: Lung Cancer

Interventions: Drug: EGF816
Drug: Gefitinib

First Posted Date: 2017-09-25

Last Posted Date: 2024-07-29

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 11

Registration Number: NCT03292133

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Efficacy and Safety of Precision Therapy in Refractory Tumor

Phase 2

Conditions: Rare Tumor
Refractory Tumor

Interventions: Drug: Gefitinib
Drug: Erlotinib
Drug: Afatinib
Drug: Trastuzumab
Drug: Oxazolidine
Drug: Olaparib
Drug: Everolimus
Drug: Cabozantinib
Drug: Vemurafenib
Drug: Dabrafenib
Drug: Palbociclib
Drug: PD-1/L1 inhibitor plus anti-angiogenic agent

First Posted Date: 2017-08-03

Last Posted Date: 2022-03-04

Lead Sponsor: Baodong Qin

Target Recruit Count: 300

Registration Number: NCT03239015

Locations: 🇨🇳
Shanghai Changzheng Hospital, Shanghai, Shanghai, China

Clinical Trial of Neoadjuvant Targeted Treatment to NSCLC Patients

Phase 3

Not yet recruiting

Conditions: 2-year Disease-Free Survival

Interventions: Drug: Oral Navelbine + Carboplatin
Drug: Gefitinib

First Posted Date: 2017-06-29

Last Posted Date: 2017-06-29

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 590

Registration Number: NCT03203590

Locations: 🇨🇳
Shenzhen People's Hospital, Shenzhen, Guangdong, China
🇨🇳
Dongguan People's Hospital, Dongguan, Guangdong, China
🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

and more 2 locations

Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer

Phase 2

Completed

Conditions: Stomach Neoplasms

Interventions: Drug: Sunitinib
Drug: Imatinib
Drug: Gefitinib

First Posted Date: 2017-05-30

Last Posted Date: 2022-06-15

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 66

Registration Number: NCT03170180

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Bone Metastasis on the Survival of Gefitinib Effective Patients

Not Applicable

Completed

Conditions: Overal Survival, Non-small Cell Lung Cancer

Interventions: Drug: Gefitinib

First Posted Date: 2017-05-17

Last Posted Date: 2017-05-17

Lead Sponsor: Qilu Hospital of Shandong University

Target Recruit Count: 265

Registration Number: NCT03157310

Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

Phase 1

Active, not recruiting

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Gefitinib
Drug: Osimertinib

First Posted Date: 2017-04-21

Last Posted Date: 2024-05-14

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 48

Registration Number: NCT03122717

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone

Phase 2

Recruiting

Conditions: Advanced Solid Tumors Which Are cMET-dependent

Interventions: Drug: Capmatinib
Drug: Nazartinib
Drug: Gefitinib
Drug: Osimertinib

First Posted Date: 2017-02-02

Last Posted Date: 2024-11-27

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 40

Registration Number: NCT03040973

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇪🇸
Novartis Investigative Site, Madrid, Spain

A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: NSCLC

Interventions: Drug: Fruquintinib
Drug: Gefitinib

First Posted Date: 2016-11-29

Last Posted Date: 2019-11-15

Lead Sponsor: Hutchison Medipharma Limited

Target Recruit Count: 50

Registration Number: NCT02976116

Locations: 🇨🇳
The First Hospital of Zhejiang University, Hangzhou, China
🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy